Iambic Therapeutics, Inc.

About Iambic Therapeutics, Inc.

Iambic Therapeutics is a biotechnology company leveraging a cutting-edge, AI-driven platform to revolutionize drug discovery and develop superior medicines. Utilizing physics-based AI algorithms and high-throughput experimental processes, Iambic addresses challenging design problems to generate optimized drug candidates and explore novel mechanisms of action. Their platform-driven pipeline focuses on first-in-class and best-in-class programs, including a HER2 program already in Phase 1 clinical studies, aimed at unlocking the potential of known targets and transforming undruggable targets into breakthrough treatments for patients with unmet medical needs. This innovative approach enables them to deliver differentiated clinical candidates at an accelerated pace, supported by over $100 million raised in an oversubscribed financing round to advance their portfolio.